Compare Unichem Lab with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB ASTRAZENECA PHARMA UNICHEM LAB/
ASTRAZENECA PHARMA
 
P/E (TTM) x 60.6 86.7 69.9% View Chart
P/BV x 0.7 24.4 2.7% View Chart
Dividend Yield % 2.1 0.0 -  

Financials

 UNICHEM LAB   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-19
ASTRAZENECA PHARMA
Mar-18
UNICHEM LAB/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2921,278 22.8%   
Low Rs182883 20.6%   
Sales per share (Unadj.) Rs167.7228.4 73.4%  
Earnings per share (Unadj.) Rs-3.610.4 -35.0%  
Cash flow per share (Unadj.) Rs5.916.3 36.5%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %1.70-  
Book value per share (Unadj.) Rs372.398.8 376.9%  
Shares outstanding (eoy) m70.3825.00 281.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.44.7 29.9%   
Avg P/E ratio x-65.3104.2 -62.6%  
P/CF ratio (eoy) x39.966.4 60.0%  
Price / Book Value ratio x0.610.9 5.8%  
Dividend payout %-110.20-   
Avg Mkt Cap Rs m16,68027,008 61.8%   
No. of employees `0002.61.4 191.9%   
Total wages/salary Rs m2,3931,535 155.9%   
Avg. sales/employee Rs Th4,535.24,210.9 107.7%   
Avg. wages/employee Rs Th919.81,132.2 81.2%   
Avg. net profit/employee Rs Th-98.2191.1 -51.4%   
INCOME DATA
Net Sales Rs m11,8015,710 206.7%  
Other income Rs m984123 803.3%   
Total revenues Rs m12,7855,833 219.2%   
Gross profit Rs m-835463 -180.4%  
Depreciation Rs m674147 457.1%   
Interest Rs m750-   
Profit before tax Rs m-600438 -136.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-343179 -192.0%   
Profit after tax Rs m-256259 -98.6%  
Gross profit margin %-7.18.1 -87.3%  
Effective tax rate %57.340.8 140.2%   
Net profit margin %-2.24.5 -47.7%  
BALANCE SHEET DATA
Current assets Rs m20,3843,209 635.2%   
Current liabilities Rs m5,0292,070 243.0%   
Net working cap to sales %130.120.0 651.9%  
Current ratio x4.11.6 261.4%  
Inventory Days Days10572 144.8%  
Debtors Days Days13535 386.2%  
Net fixed assets Rs m9,023790 1,141.8%   
Share capital Rs m14150 281.6%   
"Free" reserves Rs m26,0582,419 1,077.1%   
Net worth Rs m26,1992,469 1,061.0%   
Long term debt Rs m00-   
Total assets Rs m31,4964,605 683.9%  
Interest coverage x-7.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.41.2 30.2%   
Return on assets %-0.65.6 -10.2%  
Return on equity %-1.010.5 -9.3%  
Return on capital %-2.017.7 -11.3%  
Exports to sales %69.40-   
Imports to sales %00-   
Exports (fob) Rs m8,188NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m8,188300 2,733.4%   
Fx outflow Rs m5962,015 29.6%   
Net fx Rs m7,592-1,715 -442.6%   
CASH FLOW
From Operations Rs m-3,27888 -3,728.9%  
From Investments Rs m-2,860-94 3,055.7%  
From Financial Activity Rs m-24NA-  
Net Cashflow Rs m-4,690-6 82,284.2%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 15.1 0.3 5,033.3%  
FIIs % 3.0 15.7 19.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 9.1 348.4%  
Shareholders   20,176 12,856 156.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare UNICHEM LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Oct 22, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS